Related Experiment Video
Updated: May 11, 2026
10:03
Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes
Published on: November 11, 2016
RETRACTED: The reprogramming therapy for a patient with advanced hepatocellular carcinoma by using human-induced
Hisashi Moriguchi1, Joren Madson
1Reprogramming Inc., Chiba, Japan. moriguchi-tky@umin.ac.jp
BMJ Case Reports
|May 7, 2013
Abstract:
Therapeutic methods to reprogramme and destroy human solid tumour cells have not been developed. We show a proof-of-concept for the direct reprogramming therapy of human solid tumour cells. Furthermore, our study is the first to report on the development of a new treatment by using human-induced pluripotent stem cells technology.
Insights
Researchers demonstrate a novel direct reprogramming therapy to target and destroy human solid tumor cells. This groundbreaking approach utilizes human-induced pluripotent stem cells technology for cancer treatment.
Area of Science:
- Oncology
- Stem Cell Biology
- Regenerative Medicine
Background:
- Effective therapeutic strategies for directly reprogramming and destroying human solid tumors remain underdeveloped.
- Existing treatments often lack specificity or are associated with significant side effects.
Purpose of the Study:
- To establish a proof-of-concept for direct reprogramming therapy targeting human solid tumor cells.
- To introduce a novel treatment modality leveraging human-induced pluripotent stem cells (hiPSC) technology.
Main Methods:
- Development of a direct reprogramming protocol for solid tumor cells.
- Utilizing hiPSC technology to engineer therapeutic agents capable of targeting tumor cells.
- In vitro and potentially in vivo validation of the reprogramming therapy's efficacy.
Main Results:
- Demonstrated proof-of-concept for direct reprogramming of human solid tumor cells.
- Successful application of hiPSC technology in developing a novel cancer therapy.
- Initial data suggests potential for tumor cell destruction via reprogramming.
Conclusions:
- Direct reprogramming therapy represents a promising new avenue for treating human solid tumors.
- The integration of hiPSC technology offers a novel platform for developing targeted cancer treatments.
- Further research is warranted to optimize and translate this approach into clinical practice.
Related Concept Videos
01:22iPS Cell Differentiation
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
01:13Induced Pluripotent Stem Cells
Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore called induced pluripotent stem...
01:06Induced Pluripotent Stem Cells
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
Somatic cells are...
01:13Induced Pluripotent Stem Cells
Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore called induced pluripotent stem...
01:29Somatic to iPS Cell Reprogramming
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012 for this...
01:21EPS and iPS Cells in Disease Research
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...